HBIO Harvard Bioscience Inc.

Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET

Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET

HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on March 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. 

Participants who would like to join the call and ask a question must register . Once registered, you will receive the dial-in numbers and a unique PIN number. 

Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website .

Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the section of Harvard Bioscience’s website. 

About Harvard Bioscience 

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at .

Company Contact:

Mark Frost

Interim Chief Financial Officer

(508) 893-3120





EN
26/02/2026

Underlying

HBIOHarvard Bioscience Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Harvard Bioscience Inc.

Free Trial
HBIO Harvard Bioscie...

Harvard Bioscience Inc: 3 directors

Two Directors at Harvard Bioscience Inc bought 31,000 shares at between 4.870USD and 4.934USD. The significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...

HBIO HARVARD BIOSCIENCE INC.
6h / 49m 6h / 49m 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financi...

Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7%Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7%Interim CFO Mark Frost Appointed CFO on Permanent BasisIntroduces Full Year 2026 Guidance which Reflects Anticipated Revenue Growth Driven by New Products for Translational Science HOLLISTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the fourth quarter and full year ende...

March 12, 2026 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Announces Reverse Stock Split

Harvard Bioscience Announces Reverse Stock Split Harvard Bioscience’s common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a global leader in life science research tools, today announced that its board of directors approved the Company’s 1-for-10 reverse stock split (the “Reverse Split”) of the Company’s common stock, par value $0.01 per share. The Reverse Split was approved by the stockholders of the Company at a spec...

March 6, 2026 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience to Participate in KeyBanc’s Virtual Healthcare Foru...

Harvard Bioscience to Participate in KeyBanc’s Virtual Healthcare Forum HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financial Officer, will be participating in KeyBanc Capital Markets’ Virtual Healthcare Forum on Tuesday, March 17th. A fireside chat will be broadcast from the company’s at 2:15pm ET that day. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website . About...

March 3, 2026 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference C...

Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on March 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register . Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to ...

February 26, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch